N-oxides as prodrugs of piperazine and piperidine derivatives
    8.
    发明申请
    N-oxides as prodrugs of piperazine and piperidine derivatives 有权
    N-氧化物作为哌嗪和哌啶衍生物的前药

    公开(公告)号:US20070043059A1

    公开(公告)日:2007-02-22

    申请号:US11504050

    申请日:2006-08-15

    CPC分类号: C07D263/58 C07D413/04

    摘要: The present disclosure relates to N-oxides of certain piperazine and piperidine derivatives and to methods for the preparation of these compounds. The disclosure also relates to the use of the compounds for the manufacture of a medicament giving a beneficial effect. The disclosure also relates to the use of the compounds for the manufacture of a medicament for treating or preventing a disease or condition. The disclosure further relates to the treatment of CNS-disorders, in particular the treatment of anxiety disorders, including generalized anxiety disorder and panic disorder, obsessive compulsive disorder, aggression, addiction (including craving), depression, autism, vertigo, schizophrenia and other psychotic disorders, Parkinson's disease and disturbances of cognition and memory. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.

    摘要翻译: 本公开内容涉及某些哌嗪和哌啶衍生物的N-氧化物以及这些化合物的制备方法。 本公开还涉及该化合物在制备产生有益效果的药物中的用途。 本公开还涉及化合物在制备用于治疗或预防疾病或病症的药物中的用途。 本发明还涉及中枢神经系统疾病的治疗,特别是焦虑症的治疗,包括广泛性焦虑障碍和恐慌症,强迫症,侵略,成瘾(包括渴望),抑郁症,孤独症,眩晕,精神分裂症等精神病 疾病,帕金森病和认知和记忆障碍。 化合物具有通式(1),其中符号具有说明书中给出的含义。

    New piperazine and piperidine compounds
    9.
    发明申请
    New piperazine and piperidine compounds 有权
    新的哌嗪和哌啶化合物

    公开(公告)号:US20060089366A1

    公开(公告)日:2006-04-27

    申请号:US11129465

    申请日:2005-05-16

    CPC分类号: C07D263/58 C07D413/12

    摘要: The invention relates to a group of novel piperazine and piperidine derivatives of the formula wherein Y is hydrogen, halogen, alkyl (1-3C), or CN, CF3, OCF3, SCF3, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy, X is O, S, SO or SO2, ---Z represents -C, =C or -N, R1 and R2 independently represent hydrogen or alkyl (1-3C), Q is benzyl or 2-, 3- or 4-pyridylmethyl, wich groups may be substited with one or more more substituents from the group halogen, nitro, cyano, amino, mono- or di (1-3C)alkylamino, (1-3C) alkoxy, CF3, OCF3, SCF3, (1-4C)-alkyl, (1-3C)alkylsulfonyl or hydroxy, and salts and prodrugs thereof. It has been found that these compounds have interesting pharmacological properties due to a combination of (partial) agonism towards the members of the dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors.

    摘要翻译: 本发明涉及下式的一组新的哌嗪和哌啶衍生物其中Y是氢,卤素,烷基(1-3C)或CN,CF 3,OCF 3, >,SCF 3,烷氧基(1-3C),氨基或单或二烷基(1-3C)取代的氨基或羟基,X是O,S,SO或SO 2, Z代表-C,= C或-N,R 1和R 2独立地代表氢或烷基(1-3C),Q是苄基 或2-,3-或4-吡啶基甲基,其可以被一个或多个取代基取代为卤素,硝基,氰基,氨基,单或二(1-3C)烷基氨基,(1-3C)烷氧基 ,CF 3 3,OCF 3,SCF 3,(1-4C) - 烷基,(1-3C)烷基磺酰基或羟基,和盐 及其前体药物。 已经发现,这些化合物由于(多)向多巴胺D 2受体亚家族的成员的组合以及对相关的5-羟色胺和/或去甲肾上腺素能受体的亲和力而具有令人感兴趣的药理学性质。